Breaking News

Hartford Financial Services Group Inc HIG Stock News

Hartford Financial Services Group Inc (NYSE: HIG)

Hartford Financial Services Group was off to a relatively normal day in the market today. When the opening bell rang, the stock was slightly in the red. From there, the stock quickly recovered, making it green. Since then, we’ve seen a continuation of slow, yet steady movement upward. However, minutes ago, that slow movement turned into a mad dash as the stock spiked upward. Below, we’ll talk about what we’re seeing from HIG, why, and what we’ll be watching for ahead.





What We’re Seeing From HIG

As mentioned above, Hartford Financial Services Group was off to what seemed to be a normal start to today’s trading session. When the opening bell rang, the stock was trading slightly in the red. However, it didn’t take very long to recover. Since then, we’ve seen a continuation of gains at a relatively slow pace. Nonetheless, minutes ago, things changed as the stock started spiking upward. Currently (10:47), HIG is trading at $48.99 per share after a gain of $0.45 per share (0.93%) thus far today.

Why The Stock Is Spiking

As soon as our partners at Trade Ideas alerted us that HIG was making a run for the top, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to dig up the story in this case. While the company has not released any fundamental news that would lead to such gains, we were able to find an interesting rumor in the social space.


At the moment, regardless of which social network happens to be your favorite, if you do a search for Hartford Financial Services Group, chances are that you’ll find the rumor. It is that the company is being taken over. In this case, the rumor even names Chubb (CB) as the potential buyer. However, the rumor has not been confirmed from either side as of yet.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HIG. In particular, we’re interested in learning if there is any validity to this rumor. After all, if the company is acquired, tremendous value would likely be returned to shareholders. Nonetheless, we’ll keep a close eye on the news and bring it to you as the story continues to unfold.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

CIT Group CIT Stock News

CIT Group (NYSE: CIT)

CIT Group was off to what seemed to be an overwhelmingly strong day in the market today. When the trading session opened, the stock was already trading green. From there, it started moving further and further upward. However, minutes ago, we started to notice a downward spike on the stock. Below, we’ll talk about what we’re seeing, why, and what we’ll be watching for with regard to CIT ahead.





What We’re Seeing From CIT

As mentioned above, CIT Group was off to what looked like a strong day in the market today. At the opening bell, the stock was already trading in the green and looking to go higher. Throughout the morning, we saw a continuation of positive movement, causing stronger and stronger gains. Unfortunately however, minutes ago, the stock took a turn for the worse as it started spiking downward. At the moment (10:29), CIT is trading at $41.83 per share after a gain of $0.38 per share (0.92%) thus far today.

Why The Stock Spiked Downward

In this case, our partners at Tradespoon were the first to alert us to the downward spike on CIT. As soon as they did, the CNA Finance team went to work to figure out just what was causing the movement. Unfortunately, we seem to have found what we were looking for, and it’s not good news. It seems as though the downward spike is the result of a possible investigation.


At the moment, there’s a rumor circling social media, that, if true, could prove to be very bad news for CIT Group. That rumor is that the company is under investigation by the New York Attorney General with regard to servicing practices. At this point, the rumor is unconfirmed. Nonetheless, if it is true, it can’t be good. The rumor also suggests that Nationstar Mortgage Holdings (NSM) is under investigation.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CIT. In particular, we’re interested in learning whether or not there is any validity to this rumor. We’ll keep a close eye on the news and be sure to update you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 498
Zoetis ZTS Stock News

Zoetis Inc (NYSE: ZTS)

Zoetis is having an incredibly strong start to the trading session today. When the opening bell rang, the stock was trading well into the green. From there, it climbed a bit before correcting. Nonetheless, the spike has started again. Minutes ago, the stock made a mad dash upward. Below, we’ll talk about what we’re seeing from ZTS, why, and what we’ll be watching for ahead.





What We’re Seeing From ZTS

As mentioned above, Zoetis is off to a relatively strong start in the market today. When the opening bell rang, the stock was already trading green. Shortly thereafter, we saw a spike upward before a correction. Nonetheless, the stock has stayed in the green all day. Then, minutes ago, we started to see another spike. At the moment (10:09), ZTS is trading at $53.59 per share after a gain of $0.47 per share (0.89%) thus far today.

Why The Stock Is Climbing

When we received the alert from our partners at Trade Ideas that ZTS was making another run upward, the CNA Finance team started digging to see what was causing the movement. While we were unable to find any fundamental news that would suggest that such strong gains were coming, we did find an interesting rumor.


At the moment, there’s a rumor surfacing that the company is going to be taken over soon. According to the rumor, Boehringer is interested in dominating the global space with a strong takeover, and many believe that Zoetis is the company that’s going to be taken over. However, there has been no indication from either side that this will actually be the case.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ZTS. In particular, we’re interested in learning more about this potential takeover and whether or not it’s actually going to happen. We’ll watch the news closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikipedia]

0 352
BIOLASE BIOL Stock News

BIOLASE Inc (NASDAQ: BIOL)

BIOLASE is having an incredibly strong start to today’s trading session. As soon as the opening bell rang, the stock started screaming to the top. From there, we’ve seen a continuation of big upward movement, driving the stock higher and higher. Below, we’ll talk about what we’re seeing, why, and what we’ll be watching for with regard to BIOL moving forward.





What We’re Seeing From BIOL

As mentioned above, BIOLASE is having an overwhelmingly strong start to the trading session today. As soon as the opening bell rang, the stock found itself in the midst of a spike. From there, we’ve seen a continuation of strong upward movement. At the moment (9:40), BIOL is trading at $1.60 per share after a gain of $0.09 per share (5.95%) thus far today.

Why The Stock Is Climbing

In this case, our partners at Tradespoon were the first to notify us of the gains on BIOL. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this case, it didn’t take long to uncover the story. It seems as though the gains are coming as the result of FDA news.


At the moment, there’s a ton of chatter circling 501-K approval from the FDA. It was announced that the company’s Epic Pro Laser system has indeed been approved. This is overwhelmingly positive news, as it opens the horizons quite a bit for the company’s ability to grow in the future.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching BIOL incredibly closely. In particular, we’re interested in learning more about how the company plans to move forward following the strong approval news. We’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 797
Cellceutix Corp CTIX Stock News

Cellceutix Corp (OTCMKTS: CTIX)

Cellceutix (CTIX) was the latest victim of noted short seller Mako Research, which appears to be going through their ordinary rounds of fallacious attacks, picking on the same companies in a rotary fashion, grabbing pennies when it can. But, is their style and grandeur starting to get long in the tooth losing, causing their rhetoric to lose some strength?





Granted, CTIX traded down by about ten cents on Tuesday and the volume was strong, but shrewd investors know that a good portion of that volume was orchestrated by the Mako dump crew, who coincidentally showed up today at the CTIX post and ran trading volume about 10X higher than the recent average by what appears to be a barrage of short-sale trades during the morning session.

CTIX CEO Has Some Choice Words For Mako

There is no need for me to fight the battles for CTIX, as their CEO, Leo Ehrlich, does a fine job on his own. He made sure that the market was not confused about his opinion on the newly published hit piece when he said, Mako is a pawn in an organized criminal enterprise that profits tremendously from this type of fake news that Seeking Alpha relishes publishing because it drives web traffic. There’s a reason that the courts have ruled that Seeking Alpha is not a credible news source,” He added, “We will continue to gather information on Mako and his co-conspirators.”

The Courts Opinion Of Mako And Rosen

While Mr. Ehrlich does a fine job representing, props must also be given to his legal team. Last year, the CTIX legal team sent a similar Mako attack to the recycle bin when a District Court judge published a scathing decision on its CTIX editorial, finding that the accusations had absolutely no merit whatsoever. The opinion was one of the most entertaining decisions I have read in quite a while. Not only was Mako discredited on its long-winded diatribe of inflammatory comment, so was an attorney from Rosen Law Firm, who conveniently filed a class action suit within hours of the article. This super-human legal efficiency caused the court to wonder…how could Rosen Law Firm have drafted, edited, researched, and filed such a lengthy suit in such short manner? Well, stay tuned for that part of the story, as rumor is making its way around the water cooler that Rosen Law Firm may become the poster child for unsavory sanctions by that same judge. It’s getting apparent that the court system is getting fed up with frivolous class action lawsuits that are eerily designed to act as methods of extortion rather than a means to argue legal merit. But, we shall let the judge speak to that issue, which is expected imminently.

Investing In The Real CTIX – Kevetrin

While CTIX and the short-selling players duke it out, it’s only fair that investors get some legitimate information on which to base an investment decision. CTIX is actually making strong progress in its clinical trials, advancing two compounds, Kevetrin and Purisol.

Kevetrin is demonstrating strong results in its clinical stage trial. The drug is a small molecule compound that has the potential of becoming a breakthrough cancer treatment by activating the p53 protein when targeting solid tumors. The p53 protein, which has been in focus of late, has a critical role in controlling cell mutations. Kevetrin acts to permit the normal function of the p53 pathway, allowing the body to use its natural anti-tumor defense mechanisms to ward off tumor growth. CTIX is now advancing its phase 2a trial of Kevetrin in Platinum-Resistant Ovarian Cancer. Also important to the case that CTIX is for real, Kevetrin has been granted Orphan Drug Designation by the FDA to treat Ovarian and Pancreatic cancers. And while articles may claim CTIX to be a fraud, I just can’t fathom that the FDA has been duped, whereby CTIX is producing real clinical results in an effort to disguise their real mission (stock manipulation). It’s just a bit hard to swallow.


Purisol Is Also A Potential Winner

Purisol is another strong candidate for CTIX. This compound has already demonstrated that it can successfully treat psoriasis-associated conditions. Purisol has provided strong data in two clinical trials and has shown results that even surpass the current best standard of care. On the convenience and patient compliance front, Purisol is an orally administered medication, a far more patient appreciated method of treatment than the current alternatives that require frequent doctor visits and have uncomfortable side effects and adverse events.

Purisol is a novel dermatology drug candidate that has been granted the FDA’s 505(b)2 development approach. This process streamlines the approval process by allowing the drug developer to utilize data from previously approved medications. Thus, CTIX is not put in a position whereby they will need to re-prove all of the efficacy standards of a specific ingredient in the dosage. The 505(b)2 saves considerable time and money and allows CTIX to remain multi-focused on two advancing trials.

The Next Bite Taken…CTIX Or Mako

Shareholders should stay tuned, as there is little doubt that the saga between CTIX and the land shark is far from over. Setting trader motive aside, the continued soap opera between CTIX and Mako proves that shareholders need to spend a decent amount of time vetting both the companies that they invest in, as well as sourcing the news that they read about a company.

Relying on a well written, but potentially fictitious editorial is dangerous. And those CTIX shareholders that bailed today may be sorry that they did. Mako is a declared short, and shareholders should read the articles they present as entertaining, but purposeful. Over 1.5MM shares traded in CTIX on Tuesday, over 10X its daily average. For those that think the attack was not coordinated, think again.

My point is simple. The Makos of the world will be around as long as the SEC continues to turn a blind eye in their direction. When the articles they present are fact based, they can do a shareholder well. However, when the intent is so blatantly apparent to knock a stock down, no matter the commentary, it may be best if shareholders simply left the computer and went to purchase a double mocha latte. It’s a lot easier to swallow and they won’t lose their stock during an emotional trade.

Don’t worry, though, we’ll keep you posted as to the latest developments in this ongoing battle.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 2162
QUALCOMM QCOM Stock News

QUALCOMM, Inc. (NASDAQ: QCOM)

QUALCOMM wasn’t off to the best of days in the market today. In fact, when the market opened, the stock found itself in the red. Through the morning, the stock worked to recover, finding its way to the green. However, it soon fell again, ultimately spending most of the day below the breakeven point. And then minutes ago, things went from bad to worse as the stock started to slide downward in a big way. Below, we’ll talk about what we’re seeing from QCOM, why, and what we’ll be watching for ahead.





What We’re Seeing From QCOM

As mentioned above, today hasn’t been the best of days for QUALCOMM in the market. When the trading session opened for the day, the stock was already slightly in the red. From there, it went on a slow, yet steady recovery that ended up lingering around the breakeven point. However, minutes ago, the stock started to dive in a big way. At the moment (1:25), QCOM is trading at $65.05 per share after a loss of $1.82 per share (2.72%) thus far today.

Why The Stock Is Spiking Downward

As usual, as soon as the CNA Finance team received the notification from Tradespoon that QCOM was taking a dive, we started digging to see why the fall was happening. In this case, it didn’t take long to dig up the story. It seems to be the result of a recent Bloomberg report.


According to the Bloomberg report, QUALCOMM is facing a United States antitrust case. The case is allegedly surrounding licensing, however, there hasn’t been much data released with regard to the case.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on QCOM. In particular, we’re interested in learning more about the antitrust case against the company. Given that the news came from Bloomberg, we can rest assured that this isn’t likely a rumor. However, details would be great! We’ll be following the story and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 1231
Western Digital Corp WDC Stock News

Western Digital Corp (NASDAQ: WDC)

Western Digital Corp is having an incredibly strong day in the market today. While the stock was in the red at the opening bell, it didn’t take much time for it to work to the green. From there, we’ve seen slow, yet steady gains overall with the occasional dip. Nonetheless, minutes ago, the stock started to spike upward. Below, we’ll talk about what we’re seeing from WDC, why, and what we’ll be watching for ahead.





What We’re Seeing From WDC

As mentioned above, Western Digital Corp has been having a relatively strong day in the market thus far today. At the beginning, the stock started the day off in the red. However, within minutes, it was in the green, where it has been throughout the rest of the day. Minutes ago, things went from good to great as the stock started spiking further. Currently (12:06), WDC is trading at $71.90 per share after a gain of $0.90 per share or 1.27% thus far today.

Why The Stock Is Gaining

Our partners at Trade Ideas were the first to inform us of the gains on WDC. As soon as they did, the CNA Finance team started digging around to see exactly what was causing the movement. It didn’t take long to dig up the dirt. It seems as though the gains are being caused by the idea that an investment negotiation is in the process.


Minutes ago, a rumor started to surface that Toshiba was in investment negotiations with Western Digital Corp. The idea is that they are in the process of negotiating a semiconductor business spin off. However, the rumor is unconfirmed at the moment.

What We’ll Be Watching Moving Forward

Moving forward, the CNA Finance team will be keeping a close eye on WDC. In particular, we’re interested in learning if there is any validity to this rumor. Nonetheless, we’ll keep a close eye on the news and bring the story to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 474
Lannet Company, Inc. LCI Stock News

Lannet Company, Inc. (NYSE: LCI)

Lannett company is off to an overwhelmingly rough day in the market today. When the market opened, the stock spiked downward. While it has been on a slow, yet steady upward trend for some time now, the stock has been in the red all day and hasn’t looked like a full recovery would be possible. Now, the stock is spiking further down on a report from Citron Research. Below, we’ll talk about what we’re seeing from LCI, why, and what we’ll be watching for ahead.





What We’re Seeing From LCI

As mentioned above, Lannett Company isn’t having the best of days in the market today. Unfortunately, the stock went on a dive early on. After trying to recover, the stock was still nowhere near the break even point. Nonetheless, things went from bad to worse in what seemed like no time flat just minutes ago as it started spiking further downward. Currently (11:43), LCI is trading at $18.90 per share after a loss of $1.40 per share or 6.90% thus far today.

Why The Stock Is Falling

Our partners at Trade Ideas were the first to inform us of the declines on LCI. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this particular case, it didn’t take long to find the story. It seems as though the declines are being caused by the fact that Citron Research just took a swipe at the stock.


Recently, Lannett Company settled a lawsuit for what seemed to be a good price. However, this is just one of thousands of cases the company is facing at the moment, as mentioned in previous posts here on CNA Finance. These cases have the ability to completely bankrupt LCI, and today, Citron released a report saying the same. Here’s the tweet by Citron Research that started the movement.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on LCI. In particular, we are interested to see how the company does in ongoing legal battles it faces. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 823
Caterpillar CAT Stock News

Caterpillar Inc. (NYSE: CAT)

Caterpillar wasn’t having the best of days in the market today. In fact, as soon as the opening bell rang, the stock found itself in the red. While we’ve seen some ups and some downs throughout the day, the stock has stayed in the red since the open. Unfortunately, minutes ago, with a large spike downward, things went from bad to worse. Below, we’ll talk about what we’re seeing from CAT, why, and what we’ll be watching for ahead.





What We’re Seeing From CAT

As mentioned above, Caterpillar was already off to a rough start to the trading session today. Starting in the red at the opening bell, the stock continued on a downward path early on. While we saw some ups and we saw some downs, the stock ultimately remained in the red throughout the trading session. Unfortunately however, things have gone from bad to worse over the past few minutes as the stock spikes downward. Currently (11:25), CAT is trading at $93.65 per share after a loss of $0.83 per share or 0.88% thus far today.

Why The Stock Is Falling

Our partners at Tradespoon were the first to notify us of the downward spike on CAT. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this particular case, it didn’t take long to dig up the story. While the company hasn’t released any fundamental news that would lead to declines, there is a rumor surfacing in the social space that’s likely the cause of the drop.


Going to your favorite social network and searching for Caterpillar stock, you’ll likely see the rumor too. The rumor is that the well known hedge fund manager, founder and president of Greenlight Capital is short the stock. Of course, this would mean that he is expecting for the stock to fall. Nonetheless, at this point, the rumor is unconfirmed.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching CAT closely. In particular, we’re interested in learning about the validity of these rumors. If Einhorn is short, we may just be seeing the tip of the iceberg. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

Gevo Inc GEVO Stock News

Gevo, Inc. (NASDAQ: GEVO)

Gevo is having an incredibly strong day in the market today. When the opening bell rang, the stock found itself well in the green. While it has corrected a bit from opening highs, the stock is still sitting on incredibly impressive gains. Below, we’ll talk about what we’re seeing from GEVO, why, and what the CNA Finance team will be watching with regard to the stock ahead.





What We’re Seeing From GEVO

As mentioned above, Gevo is having a great day in the market so far. When the trading session opened for the day, the stock was already trading well into the green. From there, it did come off of highs a bit, but the gains are still impressive, and now it seems as though the stock may start inching back upward to highs. Currently (10:44), GEVO is trading at $4.35 per share after a gain of $0.63 per share or 16.93% thus far today.

Why The Stock Is Up

One of our readers tipped us off about this news. As soon as they did, the CNA Finance team started digging to see what was happening. In this particular case, it took us no time at all to dig up the story. It seems as though the GEVO gains are being caused by news announced surrounding the United States Environmental Protection Agency.


According to an announcement made by GEVO early this morning, the EPA has approved the pathway for isobutanol produced at the company’s Luverne, MN production facility to be an advanced biofuel under the Renewable Fuel Standard Program. This is huge news as it marks the first time the EPA has approved a pathway for an advanced biofuel that uses starch from feed corn to produce an alcohol. In a statement, Dr. Patrick Gruber, CEO at Gevo, had the following to offer…

The new EPA pathway combines the lowest cost carbohydrate feedstock sources with green energy, resulting in advanced fuels with a significant GHG reduction. It is worth noting that this pathway leads to the only advanced biofuel that has potential to significantly lower GHG’s while also generating large amounts of protein for animal feed. In fact, practically all of the protein from the feed corn used gby Gevo is captured and sold for animal feed. This feed corn, which is not used for human consumption, and which is supplied to Gevo in Luverne is what the local farmers are calling “low carbon corn” because of the advanced farming techniques they use to minimize chemical inputs, the low till/no till fields that are building up soil carbons and the high yields that they achieve which minimizes land use. We are pleased that there is now a route for advanced fuels that provides protein that contributes to the food system. We expect that the approval of this pathway will open up new business opportunities for Gevo, while driving sustainable environmental improvements…”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on GEVO. While the stock has been reeling a bit since the reverse split, things are starting to look up yet again. Nonetheless, we’ll be keeping a close eye on the news and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

Thought Leader Discussions

Josh Disbrow head shot1 (1)

0 1412
Aytu Bioscience Inc (OTCMKTS: AYTU) Recently, the CNA Finance team had an opportunity to speak with Josh Disbrow, CEO of Aytu Bioscience. Josh Disbrow has...